Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

ConclusionThe therapeutic landscape of MCC is rapidly evolving: many open issues will probably be resolved, and many other questions are likely to arise in the next few years. The results of ongoing prospective clinical trials and of several other studies on these issues are eagerly awaited.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research